Searle product in human trials A new kind of anti-Aids compound, developed at Oxford and Cambridge, is now being tested in humans in the USA. G D Searle, which owns the patent to the compound, known as SC-48334, has announced that phase I clinical trials began at the end of March. SC-48334 is throught to be a glucosidase inhibitor, a class of compounds studied at Oxford's glycobiology unit, funded by Searle.
'The crucial factor will be the side-effects, because in the test tube this looks very good indeed, says Professor Robert Dwek, head of the Oxford glycobiology unit at Oxford. 'If in fact there are no side-effects, it may be given to patients in an early stage of the disease, and so help prevent the disease.'
The new compound is less toxic than AZT, the only licensed AIDS …
Комментариев нет:
Отправить комментарий